Shannon Hall - Bio Rad President

BIO Stock  USD 349.56  9.04  2.65%   

President

Ms. Shannon Hall is Executive Vice President, President, Life Science Group of the Company. Previously, she was Vice President and General Manager of the Laboratory Separations Division, Life Science Group from 2008 to 2014. Prior to that, she held various positions within our Life Science Group since joining BioRad in 1992, including Division Marketing Manager of each of the Laboratory Separations Division and Gene Expression Division, Business Unit Marketing Manager of the Molecular Biology Business Unit, as well as several product manager positions. since 2014.
Age 46
Tenure 10 years
Address 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
Phone510 724 7000
Webhttps://www.bio-rad.com
Hall was with BioRad for 22 years and during that time has held several marketing positions in the Life Science Group beginning with Product Manager and later Business Unit Marketing Manager of the Molecular Biology Business Unit. In 2003, she was named Division Marketing Manager for the Gene Expression Division. In 2007, she transferred to the position of Division Marketing Manager for the Laboratory Separations Division. For the last six years, Ms. Hall led the Lab Separations Division.

Bio Rad Management Efficiency

The company has Return on Asset of 0.0177 % which means that on every $100 spent on assets, it made $0.0177 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0694) %, meaning that it generated no profit with money invested by stockholders. Bio Rad's management efficiency ratios could be used to measure how well Bio Rad manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to drop to 0.03. In addition to that, Return On Assets is likely to grow to -0.05. At this time, Bio Rad's Total Assets are very stable compared to the past year. As of the 28th of March 2024, Non Current Assets Total is likely to grow to about 9.7 B, though Non Currrent Assets Other are likely to grow to (1.4 T).
The company has 1.41 B in debt with debt to equity (D/E) ratio of 0.16, which may show that the company is not taking advantage of profits from borrowing. Bio-Rad Laboratories has a current ratio of 5.39, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Bio Rad until it has trouble settling it off, either with new capital or with free cash flow. So, Bio Rad's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bio-Rad Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bio to invest in growth at high rates of return. When we think about Bio Rad's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

PRESIDENT Age

Bruce SteelEquillium
50
Rebecca TaubMadrigal Pharmaceuticals
66
Michele TrucksisSeres Therapeutics
64
Bruce CFAEquillium
58
Wael HashadSeres Therapeutics
N/A
Marc SchneebaumMadrigal Pharmaceuticals
64
Eilon AsculaiMediwound
N/A
Craig PhilipsKineta Inc
63
Marcus ChapmanSeres Therapeutics
47
Wendy RiederMadrigal Pharmaceuticals
46
Thomas DesRosierSeres Therapeutics
63
Kevin HorganSeres Therapeutics
58
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Bio-Rad Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 8200 people. Bio Rad Laboratories (BIO) is traded on New York Stock Exchange in USA. It is located in 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 and employs 8,030 people. Bio Rad is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Bio-Rad Laboratories Leadership Team

Elected by the shareholders, the Bio Rad's board of directors comprises two types of representatives: Bio Rad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Rad's management team and ensure that shareholders' interests are well served. Bio Rad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Rad's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Stark, Principal Accounting Officer, Vice President Controller
Ajit Ramalingam, Senior Vice President Chief Accounting Officer
Shannon Hall, Executive Vice President and Presidentident, Life Science Group
Jeffrey Edwards, Independent Director
Lee Boyd, Senior Pacific
Andrew Last, Chief Operating Officer, Executive Vice President
Yong Chung, Vice Relations
Tania DeVilliers, Corporate Director
Arnold Pinkston, Independent Director
Christine Tsingos, CFO and Executive VP
Timothy Ernst, Executive Vice President General Counsel and Secretary
Ronald Hutton, Vice President Treasurer
Joel McComb, Director
Jim Barry, Senior Manufacturing
Alice Schwartz, Director
Gregory Hinckley, Lead Independent Director
Michael Crowley, Executive Vice President - Global Commercial Operations
Simon May, Executive Vice President and Presidentident - Life Science Group
Melinda Litherland, Independent Director
John Hertia, Executive Vice President, President, Clinical Diagnostics Group
John Goetz, COO and Executive VP
Louis Drapeau, Independent Director
Shawn Soderberg, Executive Vice President General Counsel, Secretary
Annette Tumolo, Executive Vice President and Presidentident, Life Science Group
Dara Wright, Executive Vice President and President of the Clinical Diagnostics Group
Norman Schwartz, Chairman of the Board, President, Chief Executive Officer
Ilan Daskal, Chief Financial Officer, Executive Vice President
Matthew Werner, Senior Officer
Colleen Corey, Executive Resources
Deborah Neff, Independent Director
Giovanni Magni, Executive Vice President, Chief Strategy Officer
Robert Malchione, Independent Director

Bio Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Rad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Bio Rad

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bio Stock

  0.81EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Bio Stock

  0.69MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.65KA Kineta Inc Report 29th of March 2024 PairCorr
  0.63MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.62VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.58MBIO Mustang Bio Report 3rd of April 2024 PairCorr
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio-Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bio-Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Bio Stock analysis

When running Bio Rad's price analysis, check to measure Bio Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Rad is operating at the current time. Most of Bio Rad's value examination focuses on studying past and present price action to predict the probability of Bio Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Rad's price. Additionally, you may evaluate how the addition of Bio Rad to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bonds Directory
Find actively traded corporate debentures issued by US companies
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is Bio Rad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.56)
Earnings Share
(21.83)
Revenue Per Share
91.453
Quarterly Revenue Growth
(0.07)
Return On Assets
0.0177
The market value of Bio-Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.